stockrowInsmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
Follow INSM
Alert me
Insmed, Inc. (INSM) Free cash flow
Insmed, Inc.'s free cash flow for fiscal 2025 was −$967.6M, compared with −$705.8M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$627.6M. Over the past ten years it has ranged from −$967.6M (fiscal 2025) to −$104.2M (fiscal 2015) — the current reading is the lowest in ten years. Free cash flow has fallen for 5 consecutive fiscal years. Insmed, Inc. ranks 598th of 603 Biotechnology companies by free cash flow.
Free cash flow, annual
Embed this chart
Annual newest first
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | −$967.6M | — |
| FY2024 | −$705.8M | — |
| FY2023 | −$549.5M | — |
| FY2022 | −$410.3M | — |
| FY2021 | −$370.6M | — |
| FY2020 | −$226.2M | — |
| FY2019 | −$292.9M | — |
| FY2018 | −$272.8M | — |
| FY2017 | −$162.6M | — |
| FY2016 | −$150.9M | — |
Quarterly newest first
| Period | Free cash flow | Change |
|---|---|---|
| Sep 2026 | −$42.1M | — |
| Jun 2026 | −$95.1M | — |
| Mar 2026 | −$226.2M | — |
| Dec 2025 | −$264.2M | — |
| 43 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| EXEL Exelixis, Inc. compare | $1.1B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $806.3M |
| INCY Incyte Corporation compare | $679.9M |
| ASND Ascendis Pharma A/S compare | $387.5M |
| BBIO BridgeBio Pharma, Inc. compare | −$369.8M |
| BNTX BioNTech SE Sponsored ADR compare | −$524.1M |
| INSM Insmed, Inc. | −$627.6M |
| ROIV Roivant Sciences Ltd. compare | −$821.1M |
| GMAB Genmab A/S Sponsored ADR compare | −$6.3B |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on INSM
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement